Latest Trials Latest NewsFAQ

BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Phase 2

Completed

Conditions: Vascular Diseases

Interventions: Drug: Atorvastatin
Other: Placebo
Drug: BMS-582949
Drug: Statin

First Posted Date: 2007-12-11

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72

Registration Number: NCT00570752

Locations: 🇺🇸
Florida Cardiovascular Institute, Tampa, Florida, United States
🇺🇸
Troy Internal Medince Pc/Research, Troy, Michigan, United States
🇺🇸
Baylor College Of Medicine, Houston, Texas, United States

and more 13 locations

Subcutaneous Pharmacokinetics of Belatacept

Phase 1

Completed

Conditions: Transplantation

Interventions: Drug: belatacept
Drug: Placebo

First Posted Date: 2007-12-07

Last Posted Date: 2016-09-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 153

Registration Number: NCT00569803

Locations: 🇺🇸
Ppd Development, Austin, Texas, United States

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Solid Tumors
Metastases

Interventions: Drug: BMS-754807

First Posted Date: 2007-12-06

Last Posted Date: 2013-08-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 63

Registration Number: NCT00569036

Locations: 🇦🇺
Local Institution, Nedlands, Western Australia, Australia

Dasatinib in Combination With Revlimid (and Dexamethasone)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
Drug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
Drug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
Drug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
Drug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg

First Posted Date: 2007-11-19

Last Posted Date: 2016-08-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT00560391

Locations: 🇫🇷
Local Institution, Vandoeuvre Les Nancy, France
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Dasatinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2007-11-19

Last Posted Date: 2017-03-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT00560352

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇪🇸
Local Institution, Salamanca, Spain

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-650032 or Placebo

First Posted Date: 2007-11-16

Last Posted Date: 2010-09-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT00559247

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇺🇸
Parexel International Corporation, Baltimore, Maryland, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 2 locations

Methotrexate-Inadequate Response Study

Phase 3

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Intravenous (IV) Abatacept
Drug: Subcutaneous (SC) Abatacept

First Posted Date: 2007-11-16

Last Posted Date: 2015-11-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2492

Registration Number: NCT00559585

Locations: 🇺🇸
Rheumatic Disease Clinical Research Center, Llc, Houston, Texas, United States
🇺🇸
Accurate Clinical Research, Houston, Texas, United States
🇺🇸
Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, United States

and more 67 locations

Belatacept in Liver Transplant Recipients

Phase 2

Terminated

Conditions: Immunosuppression in Solid Organ Transplant

Interventions: Drug: Belatacept Less Intensive (LI)
Drug: Basiliximab
Drug: Tacrolimus
Drug: Belatacept More Intensive (MI)
Drug: Mycophenolate Mofetil (MMF)

First Posted Date: 2007-11-08

Last Posted Date: 2012-10-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 260

Registration Number: NCT00555321

Locations: 🇺🇸
Usc University Hospital, Los Angeles, California, United States
🇺🇸
Westchester Medical Center, Valhalla, New York, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States

and more 17 locations

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: Epofolate

First Posted Date: 2007-10-26

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT00550017

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇬🇧
Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Phase 3

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: abatacept
Drug: Methotrexate (MTX)

First Posted Date: 2007-10-22

Last Posted Date: 2015-03-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 119

Registration Number: NCT00547521

Locations: 🇺🇸
Columbia Arthritis Center, Columbia, South Carolina, United States
🇺🇸
Boulder Medical Center, Boulder, Colorado, United States
🇺🇸
Physicians East, Pa, Greenville, North Carolina, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy